First Alzheimer’s disease patients treated with anti-dementia drugs: sustained benefits for some patients
pdf

Keywords

Alzheimer’s disease
Dementia
Anticholinesterase

Abstract

 

 

 

https://doi.org/10.48037/mbmj.v4i1.728
pdf

References

National Institute for Clinical Excellence. Guidance on the use of Donepezil, Rivastigmine and Galanthamine for the treatment of Alzheimer' Disease. Technology Appraisal Guidance No 19 January 2001

Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT and the Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of Donepezil in patients with Alzheimer's disease. Neurology 1998;50:136-145. Available from: https://doi.org/10.1212/wnl.50.1.136

Burns A, Rossor M, Guathier S, et al. and the Donepezil Study Group. The effects of donepezil in Alzheimer's Disease -results from a multinational trial. Dement Geriat Cogn Disord 1999;10:237-244. Available from: https://doi.org/10.1159/000017126

Folstein MF, Folstein SE, McHugh PR. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psych Res 1975;12:189-198. Available from: https://doi.org/10.1016/0022-3956(75)90026-6

Roth M, Tym E, Mountjoy CQ, et al. CAMDEX - A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br J Psych 1986; 149:698-709. Available from: https://doi.org/10.1192/bjp.149.6.698